101 completed, 25 terminated, 13 unknown, 6 not yet recruiting. 46 Phase 3, 45 Phase 2, 34 Phase 4, 22 Phase 1, 16 Not applicable.
Follow Chloroquine: new trials by email Literature Review of Chloroquine trials Research Report on Chloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax | Phase 2 | Not yet recruiting | R. Kiplin Guy | 104 | 2026-12-01 | 2026-10-21 |
| Ethiopian Antimalarial Therapeutic Efficacy Study 2026 Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine - Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated) | Not yet recruiting | Ethiopian Public Health Institute | 1200 | 2026-10-20 | 2026-09-25 | |
| Tafenoquine Drug Levels in Small Children Chloroquine, Tafenoquine - Plasmodium Vivax Malaria, Vivax Malaria | Phase 2 | Not yet recruiting | University of Oxford | 20 | 2026-09-01 | 2026-09-22 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax Tafenoquine (TQ), Chloroquine (CQ), Dihydroartemisinin-piperaquine (DHA-PPQ) - Uncomplicated P. Vivax Mono-infection | Not applicable | Not yet recruiting | Walter Reed Army Institute of Research (WRAIR) | 300 | 2026-05-01 | 2026-04-16 |
| The Seven Trial: Exploiting the Unfolded Protein Response Botensilimab, Balstilimab, Chloroquine Phosphate - Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic | Phase 1 | Terminated | HonorHealth Research Institute | 6 | 2025-01-09 | 2026-06-23 |
| An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older Tafenoquine, Primaquine, Chloroquine - Malaria, Vivax | Phase 3 | Recruiting | GlaxoSmithKline | 324 | 2024-11-13 | 2026-10-01 |
| Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine-pyrimethamine-amodiaquine - Malaria,Falciparum, Anemia in Children | Phase 4 | Completed | Liverpool School of Tropical Medicine | 788 | 2024-10-14 | 2026-07-30 |
| Southeast Asia Dose Optimization of Tafenoquine Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg - Plasmodium Vivax Malaria | Phase 4 | Recruiting | University of Oxford | 820 | 2024-07-22 | 2026-10-09 |
| The Addition of Chloroquine to Chemoradiation for Glioblastoma, Chloroquine - Glioblastoma, Astrocytoma, Grade IV | Phase 2 | Withdrawn | Maastricht Radiation Oncology | 2023-11-10 | 2023-11-18 | |
| ACT vs CQ With Tafenoquine for P. Vivax Mono-infection Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose), Chloroquine plus Tafenoquine (450 mg adult dose), Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose) - Malaria, Malaria, Vivax | Phase 4 | Recruiting | Shoklo Malaria Research Unit | 606 | 2023-06-26 | 2025-05-16 |
| Comparing Chemoprevention Drugs for School-based Malaria Control Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine pyrimethamine - Malaria,Falciparum, Anemia in Children | Phase 4 | Completed | University of Maryland, Baltimore | 646 | 2023-02-13 | 2023-08-07 |
| Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax Chloroquine, Primaquine - Efficacy, Malaria | Phase 4 | Completed | Dinka Dugassa | 100 | 2022-12-19 | 2023-09-22 |
| Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer Hydroxychloroquine Combined With Gemcitabine - Hydroxychloroquine, Gemcitabine | Phase 2 | Unknown | Henan Cancer Hospital | 55 | 2022-12-15 | 2022-12-12 |
| Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield PART, Malakit, CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS - Malaria, Vivax | Not applicable | Completed | Centre Hospitalier de Cayenne | 1991 | 2022-09-12 | 2025-07-24 |
| Comparing Chemoprevention Approaches for School-based Malaria Control Dihydroartemisinin-Piperaquine, Chloroquine - Malaria,Falciparum, Anemia in Children | Phase 4 | Completed | University of Maryland, Baltimore | 746 | 2022-02-01 | 2022-11-15 |
| Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy Nivaquine ® (Chloroquine) - Tuberculosis Infection | Phase 1 | Unknown | University of Zurich | 16 | 2022-01-04 | 2024-07-01 |
| Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide - Glioblastoma, Gliosarcoma | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 2 | 2021-08-12 | 2025-01-15 |
| IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT Hydroxychloroquine/Chloroquine - Covid-19 Infection, Rheumatoid Arthritis | Completed | University of Alberta | 773 | 2020-11-01 | 2024-09-19 | |
| Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19 Chloroquine or hydroxychloroquine, zinc - COVID | Phase 3 | Completed | Tanta University | 191 | 2020-06-23 | 2022-04-01 |
Showing 20 of 153. Sign in to see all of them.
Malaria (57) · Malaria, Vivax (37) · Malaria, Falciparum (27) · COVID-19 (15) · Recurrence (7) · Anemia (6) · Coronavirus Infections (6) · Arthritis, Rheumatoid (4) · Glioblastoma (4) · Atherosclerosis (3) · Birth Weight (3) · Glucosephosphate Dehydrogenase Deficiency (3) · HIV Infections (3) · Hypertension (3) · Infections (3)
Pfizer (12) · London School of Hygiene and Tropical Medicine (10) · University of Oxford (10) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · GlaxoSmithKline (7) · Menzies School of Health Research (6) · Tanta University (5) · Centers for Disease Control and Prevention (4) · Maastricht Radiation Oncology (4) · Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (3) · University of Maryland, Baltimore (3) · Washington University School of Medicine (3) · Bandim Health Project (2) · Government of Punjab, Specialized Healthcare and Medical Education Department (2) · Institute of Tropical Medicine, Belgium (2)
United States (25) · Thailand (17) · Brazil (12) · Malawi (9) · Vietnam (7) · Burkina Faso (6) · India (6) · Mali (6) · Netherlands (6) · Pakistan (6) · Egypt (5) · Ethiopia (5) · Kenya (5) · Uganda (5) · Cambodia (4)
Francois Nosten, MD (3) · Cindy Chu, MD, PhD (2) · Clay F. Semenkovich, MD (2) · Jayaram Menon, MBBS (2) · Lauren Cohee, MD MS (2) · Mark W Rowland, PhD (2) · Peter Aaby (2) · Ric Price, MBBS (2) · Tsin Yeo, MBBS (2) · Alejandro L Cuentas,, MD, PhD (1)
PMID 36534705, PMID 16520474, PMID 20208057, PMID 25421474, PMID 25425434, PMID 31384309, PMID 11176912, PMID 11832638, PMID 14592603, PMID 15727424, PMID 15838784, PMID 17046467, PMID 17093247, PMID 17213921, PMID 17707447, PMID 18171245, PMID 19103632, PMID 2024970, PMID 20409302, PMID 20562526, PMID 20844049, PMID 21148503, PMID 21267072, PMID 21398612, PMID 21550310, PMID 22303437, PMID 22427705, PMID 22811794, PMID 23208422, PMID 23433102, PMID 23718705, PMID 23833120, PMID 23891088, PMID 24360369, PMID 24391139, PMID 24889179, PMID 25138814, PMID 25591391, PMID 25881046, PMID 26006260, PMID 26248362, PMID 26286026, PMID 26336062, PMID 26416102, PMID 26500351, PMID 26505753, PMID 26518132, PMID 26603174, PMID 26666916, PMID 26917051
P50HL083762 (2), 2005 (1), 2017 (1), R01AI025136 (1), R01AI103228 (1), R01AI104702 (1), U01AI068636 (1), U01AI089342 (1), U01AI195203 (1), U01CI000211 (1)